Market Place
Sourcing Support
Palatin Reveals Q2 Fy2026 Financials And Corporate Progress
17 Feb 2026 //
PR NEWSWIRE
Palatin Reveals Q1 Fy2026 Financials And Corporate Progress
13 Nov 2025 //
PR NEWSWIRE
Palatin Technologies Closes $18.2M Upsized Offering
12 Nov 2025 //
PR NEWSWIRE
Palatin Pharma Sets $15.8M Public Offering Price
06 Nov 2025 //
PR NEWSWIRE
Palatin Gets €5.5M Milestone In Retinal Deal With Boehringer
22 Sep 2025 //
PR NEWSWIRE
Palatin Declares 1-for-50 Reverse Stock Split
08 Aug 2025 //
PR NEWSWIRE
Palatin Reports FY2025 Q3 Results and Business Update
14 May 2025 //
PR NEWSWIRE
Palatin`s Preclinical Data on Melanocortin Agonists at ARVO 2025
09 May 2025 //
PR NEWSWIRE
Palatin`s Preclinical Data for PL9588 at ARVO 2025
05 May 2025 //
PR NEWSWIRE
Palatin Reports Symptom Resolution in PL9643 MELODY-1 trial
29 Apr 2025 //
PR NEWSWIRE
Palatin Appeals NYSE American Notice of Delisting
14 Apr 2025 //
PR NEWSWIRE
NYSE American to Delist Palatin Technologies (PTN)
10 Apr 2025 //
BUSINESSWIRE
Palatin reports positive Ph 2 results for oral Ulcerative Colitis study
28 Mar 2025 //
PR NEWSWIRE
Palatin Reports Q2 Fiscal Year Financial Results & Business Update
13 Feb 2025 //
PR NEWSWIRE
Palatin to Report Q2 FY2025 Results, Teleconference on Feb 13, 2025
10 Feb 2025 //
PR NEWSWIRE
Palatin Announces $4.7M Offering & Private Placement
07 Feb 2025 //
PR NEWSWIRE
Palatin Provides Update on Anticipated 2025 Corporate Milestones
28 Jan 2025 //
PR NEWSWIRE
Palatin Announces Positive Ph IIb Results in Diabetic Nephropathy
19 Dec 2024 //
PR NEWSWIRE
Palatin Announces Exercise of Warrants for $3.4M Proceeds
16 Dec 2024 //
PR NEWSWIRE
Palatin Completes Patient Enroll in Ph 2 Study of PL8177 for Colitis
25 Nov 2024 //
PR NEWSWIRE
Palatin Reports Q1 FY 2025 Financial & Operating Results
14 Nov 2024 //
PR NEWSWIRE
Palatin Receives Notice of Non-Compliance from NYSE American
07 Oct 2024 //
PR NEWSWIRE
Palatin Reports Q4 2024 Financial Results and Program Updates
01 Oct 2024 //
PR NEWSWIRE
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
26 Sep 2024 //
PR NEWSWIRE
Palatin Updates On Clinical Programs And Strategic Priorities
09 Sep 2024 //
PR NEWSWIRE
FDA Accepts Palatin`s Phase 3 Trials For PL9643 In Dry Eye Disease
28 Aug 2024 //
PR NEWSWIRE
Palatin Doses First Patient In Bremelanotide-Tirzepatide Obesity Trial
23 Aug 2024 //
PR NEWSWIRE
Palatin Announces Exercise of Warrants for $6.1 Million Gross Proceeds
21 Jun 2024 //
PR NEWSWIRE
Palatin Reports Q3 FY2024 Financials, Corporate Update
15 May 2024 //
PR NEWSWIRE
Palatin Q3 FY2024 Results, Call On May 15
09 May 2024 //
PR NEWSWIRE
Palatin Hosts KOL Event On Melanocortin Agonists On May 8
30 Apr 2024 //
PR NEWSWIRE
Palatin’s stock plummets 43% as lead asset fails PhIII dry eye primary endpoints
29 Feb 2024 //
ENDPTS
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results
15 Feb 2024 //
PR NEWSWIRE
Palatin to Report Second Quarter Fiscal Year 2024 Results
09 Feb 2024 //
PR NEWSWIRE
Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
02 Jan 2024 //
INDIAN PHARMA POST
Palatin Completes Sale of Vyleesi® to Cosette Pharma for up to $171 Million
20 Dec 2023 //
PR NEWSWIRE
Palatin Announces Quarter Ended September 30 Vyleesi Product Revenue Results
19 Oct 2023 //
PR NEWSWIRE
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results
28 Sep 2023 //
PR NEWSWIRE
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth
07 Aug 2023 //
PR NEWSWIRE
Palatin to Participate in Canaccord Genuity`s 43rd Annual Growth Conference
04 Aug 2023 //
PR NEWSWIRE
Palatin Announces Preliminary Q4 Fiscal 2023 Vyleesi® Product Revenue Results
11 Jul 2023 //
PR NEWSWIRE
Palatin Presents Preclinical Diabetic Nephropathy Data at Podocyte Conference
30 May 2023 //
PR NEWSWIRE
Palatin Reports Third Quarter Fiscal Year 2023 FYR and Provides Update
16 May 2023 //
PR NEWSWIRE
Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Conference
09 May 2023 //
PR NEWSWIRE
Palatin Technologies to Host Key Opinion Leader Webinar
01 May 2023 //
PR NEWSWIRE
Palatin reports results of dry eye disease therapy trials
28 Apr 2023 //
CLINICAL TRIALS ARENA
Palatin Presents Data at the Association of Research in Vision & Opht 2023
25 Apr 2023 //
PR NEWSWIRE
Pre-Clinical Data of Palatin`s Melanocortin Agonist Demons Therapeutic Effects
18 Apr 2023 //
PR NEWSWIRE
Palatin Issued Patent on Vyleesi For Hypoactive Sexual Desire Disorder
28 Feb 2023 //
PR NEWSWIRE
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results
15 Feb 2023 //
PR NEWSWIRE
Palatin to Report Second Quarter Fiscal Year 2023 Results
10 Feb 2023 //
PR NEWSWIRE
Palatin Receives $4.7 Million of Non-Dilutive Funding
18 Jan 2023 //
PR NEWSWIRE
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi
05 Jan 2023 //
PR NEWSWIRE
Palatin Reports First Quarter Fiscal Year 2023 Financial Results
14 Nov 2022 //
PRNEWSWIRE
Palatin to Report First Quarter Fiscal Year 2023 ResultsTeleconference & Webcast
09 Nov 2022 //
PRNEWSWIRE
Palatin Announces $10 Million Registered Direct Offering
31 Oct 2022 //
PRNEWSWIRE
Palatin Presents PL8177 Data at Annual Meeting
24 Oct 2022 //
PRNEWSWIRE
First Patient Enrolled in Palatin`s PII study of PL8177
20 Oct 2022 //
PRNEWSWIRE
Palatin Announces Publication of Vyleesi fMRI Study in Women with HSDD
17 Oct 2022 //
PRNEWSWIRE
Palatin Announces First Quarter Fiscal 2023 Vyleesi® Product Sales Results
13 Oct 2022 //
PRNEWSWIRE
